Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
efgartigimod administration · 1 trial · 1 indication
The percentage of patients who do not experience, at any time during the study, a 2 or more-point deterioration from their averaged baseline MG-ADL score that is sustained for a period of 4 or more consecutive weeks. (stable or improved patients)
| Arm | Type | Description |
|---|---|---|
| treatment | EXPERIMENTAL | Efgartigimod infusion |
| Name | Type | Description |
|---|---|---|
| efgartigimod administration | DRUG | efgartigimod infusion |
Inclusion Criteria: * 1\. Signed informed consent. 2. Age 18-80 years 3. Acetylcholine receptor antibody positive, myasthenia gravis patients, with stable disease for the past four or more months. Stable disease is defined as no change in dosage or interval in IVIG treatments and without any signif...
Efgartigimod is being studied for the treatment of Myasthenia Gravis, specifically in patients who are dependent on intravenous immunoglobulin (IVIG) therapy. It is an investigational therapy currently in Phase 3 clinical development for this condition.
Efgartigimod is being developed by argenx SE, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARGX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Myasthenia Gravis.
Efgartigimod is currently in Phase 3 clinical development for Myasthenia Gravis. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is actively recruiting participants.
Efgartigimod is being evaluated in a Phase 3 clinical trial with the identifier NCT06765161. This trial, titled 'Efgartigimod in IVIG Dependent Myasthenia Gravis Patients,' is recruiting participants in Canada and aims to enroll 30 patients aged 18 years and older.
Efgartigimod is the drug name used in the clinical trial for IVIG-dependent Myasthenia Gravis patients. The trial does not specify alternative names, so it is not confirmed whether efgartigimod is the same as efgartigimod alfa.